Olanzapine Market: Global Industry Analysis and Forecast (2021-2027) by Type, Application, and Region

By 2027, the Olanzapine Market is expected to reach US $ 3.70 billion, thanks to growth in the industrial product segment. The report analyzes Olanzapine Market dynamics by region and Application industries.

Olanzapine Market Overview:

The US Food and Drug Administration has approved Olanzapine, formerly known as Zyprexa, for the treatment of schizophrenia, bipolar disorder, and other neurological disorders. Olanzapine is a generic drug that is available under a variety of trade names all over the world. Olanzapine pills range in dosage from 2.5 to 20 milligrams and are approved in several countries. Zyprexa (and generic olanzapine) is available as an orally disintegrating "wafer" that dissolves swiftly in spit. It's also available for intramuscular injection in 10-milligram vials. Olanzapine Market To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2027. 2020 is considered a base year however 2020's numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done good in lockdown also and specific strategic analysis of those companies is done in the report

Olanzapine Market Dynamics:

Olanzapine Market size was esteemed at US$ 3.11 Bn. in 2020 and the total profits is expected to grow at 2.5% through 2021 to 2027, reaching nearly US$ 3.70 Bn. The increase in the population of various countries is the key market influencer for the worldwide Olanzapine market. As the world population grows at a rate of more than 1% per year and individuals do not receive complete neutrinos, diseases such as schizophrenia become more prevalent, driving pharmaceutical businesses to develop more pharmaceuticals to meet demand and assist consumers. According to WHO figures, 10% of the world's population is affected by various forms of dysfunctional behaviour. According to the National Center for Mental Health, China-CDC, there are more than 100 million cases of mental illnesses, with 16 million people suffering from holergasia. Emotional instability has eclipsed malignancy as the largest threat to human health in China, ranking first in the total weight of illness. The prevalence of emotional illness and mental troubles is increasing as a result of changing lifestyles and more tension in jobs and living brought on by global monetary development. As a result, the global market for olanzapine is expected to continue growing in the coming years. Additionally, during the forecast period, the global Olanzapine Market is expected to develop at a healthy rate. Increased frequency of neurological disorders such as schizophrenia, bipolar disorders, and other disorders, as well as a significant number of people with mental illness and emotional instability, have boosted demand for olanzapine as a first-line treatment for these diseases. Furthermore, the National Institute of Health and Care Excellence recommends olanzapine as a first-line treatment for bipolar illness's acute mania. In addition to these contributing variables, several additional elements have a negative impact on the market's growth, such as drug side effects and numerous regulatory requirements for marketing the drug, which may stymie the market's growth.

Olanzapine Market Segment Analysis:

The ZYPREXA Intra Muscular segment is leading the Application segment of the Olanzapine Market: Intramuscular olanzapine (Zyprexa) is a fast-acting atypical antipsychotic medication that is also indicated for the treatment of agitation in patients with schizophrenia or bipolar mania, which is the subject of this review. This formulation of olanzapine is at least as effective as intramuscular haloperidol or lorazepam in the treatment of individuals with acute agitation associated with schizophrenia or bipolar mania, according to evidence from three well-designed trials, and has a faster onset of action. Even though some people taking injectable olanzapine may experience temporary drops in heart rate and blood pressure, early evidence of a lack of clinical effect on the rectified QT (QTc) intermission and a reduced prevalenceis difficult to assess because more than half of those who participated in trials dropped out before the 6-week mark. When compared to most other second-generation antipsychotic medications used to treat schizophrenia, olanzapine (like clozapine) may cause weight gain and elevated glucose and cholesterol levels. Schizophrenia is more common in America and is likely to affect 1% of the population that is around 2.2 million Americans. Hence, the rising prevalence of the disorder is likely to grab more attention in the market.

Olanzapine MarketOlanzapine Market Regional Insights:

North America is estimated to dominate the growth of the Olanzapine Market. Due to widespread usage of the product by patients in the region and major manufacturers creating the product in the region, the North Americas has the greatest market share, accounting for about 40% of the market. Furthermore, the growing prevalence of neurological illnesses such as bipolar disorder and schizophrenia among people is fueling the growth of this market in the North American region. Despite the fact that it only affects 1% of the population, it is one of the most crippling diseases known to mankind. Schizophrenia is a chronic and severe neurological brain condition that affects about 1.1 % of the population in the United States, or about 2.6 million persons aged 18 and over also 360,000 Canadians living with schizophrenia. Hence, rising prevalence is likely to boost the growth of the market in coming future. Furthermore, the European market is gradually developing and will eventually catch up to the American market. Due to the obvious high number of people diagnosed with mental illness and neurological abnormalities, Olanzapine was initially introduced in the European region. The objective of the report is to present a comprehensive analysis of the Olanzapine Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Olanzapine Market dynamics, structure by analyzing the market segments and projecting the Olanzapine Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Olanzapine Market make the report investor’s guide.

Olanzapine Market Scope: Inquire before buying

Olanzapine Market

Olanzapine Market, by Region

• North America o US o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Sweden o CIS Countries o Rest of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest of Asia Pacific • The Middle East and Africa o South Africa o GCC Countries o Egypt o Nigeria o Rest of ME&A • South America o Brazil o Argentina o Rest of South America

Olanzapine Market Key Player

WATSON Pharmaceuticals(Changzhou) • Hanson Pharmaceutical • Sandoz • Zhejiang Langhua Pharmaceuticals • Hansoh Pharmaceutical • Aurobindo Pharma • Jubilant Lifesciencest • Torrent Pharmaceuticals • Sun Pharmaceutical • Lilly • Dr. Reddy’s Laboratories • Mylan Pharmaceuticals • Apotex Inc. • Teva Pharmaceutical FAQs: 1. What is the Olanzapine Market value in 2020? Ans: Olanzapine Market value in 2020 was estimated as 3.11 Billion USD. 2. What is the Olanzapine Market growth? Ans: The Olanzapine Market is anticipated to grow with a CAGR of 2.5% in the forecast period and is likely to reach USD 3.70 Billion by the end of 2027. 3. Which segment is expected to dominate the Olanzapine Market during the forecast period? Ans: North America is expected to dominate the global Olanzapine treatment market. Factors such as the existence of important companies, the high prevalence of Olanzapine patients in the region, and established healthcare infrastructure are some of the key factors responsible for the market's huge share. 4. Who are the key players in the Olanzapine Market? Ans: WATSON Pharmaceuticals (Changzhou), Hanson Pharmaceutical, Sandoz, Zhejiang Langhua Pharmaceuticals, Hansoh Pharmaceutical, Aurobindo Pharma, Jubilant Lifesciencest, Torrent Pharmaceuticals, Sun Pharmaceutical, Lilly, Dr. Reddy’s Laboratories, Mylan Pharmaceuticals, Apotex Inc., Teva Pharmaceutical are key players of the global olanazapine market. 5. What is the key driving factor for the growth of the Olanzapine Market? Ans: Key factors that are driving the market growth include an increase in diseases occurrence and growing drug amalgamation and increase research and development activities about available treatment.
1. Global Olanzapine Market: Research Methodology 2. Global Olanzapine Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Olanzapine Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Olanzapine Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Olanzapine Market Segmentation 4.1 Global Olanzapine Market, by Type (2020-2027) • ZYPREXA tablets • ZYPREXA ZYDIS • ZYPREXA Intra Muscular 4.2 Global Olanzapine Market, by Application (2020-2027) • Schizophrenia • Bipolar disorder • Other 4 North America Olanzapine Market (2020-2027) 4.1 North America Olanzapine Market, by Type (2020-2027) • ZYPREXA tablets • ZYPREXA ZYDIS • ZYPREXA Intra Muscular 4.2 North America Olanzapine Market, by Application (2020-2027) • Schizophrenia • Bipolar disorder • Other 4.3 North America Olanzapine Market, by Country (2020-2027) • United States • Canada • Mexico 5 Asia Pacific Olanzapine Market (2020-2027) 6.1. Asia Pacific Olanzapine Market, by Type (2020-2027) 6.2. Asia Pacific Olanzapine Market, by Application (2020-2027) 6.2. Asia Pacific Olanzapine Market, by Country (2020-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 6 Middle East and Africa Olanzapine Market (2020-2027) 7.1. Middle East and Africa Olanzapine Market, by Type (2020-2027) 7.2. Middle East and Africa Olanzapine Market, by Application (2020-2027) 2.5. Middle East and Africa Olanzapine Market, by Country (2020-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 7 Latin America Olanzapine Market (2020-2027) 8.1. Latin America Olanzapine Market, by Type (2020-2027) 8.2. Latin America Olanzapine Market, by Application (2020-2027) 8.3 Latin America Olanzapine Market, by Country (2020-2027) • Brazil • Argentina • Rest of Latin America 8 European Olanzapine Market (2020-2027) 9.1. European Olanzapine Market, by Type (2020-2027) 9.2. European Olanzapine Market, by Application (2020-2027) 9.3 European Olanzapine Market, by Country (2020-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest of Europe 9 Company Profile: Key players 10.1. Veolia 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. WATSON Pharmaceuticals (Changzhou) 10.3. Hanson Pharmaceutical 10.4. Sandoz 10.5. Zhejiang Langhua Pharmaceuticals 10.6. Hansoh Pharmaceutical 10.7. Aurobindo Pharma 10.8. Jubilant Lifesciencest 10.9. Torrent Pharmaceuticals 10.10. Sun Pharmaceutical 10.11. Lilly 10.12. Dr. Reddy’s Laboratories 10.13. Mylan Pharmaceuticals 10.14. Apotex Inc. 10.15. Teva Pharmaceutical

About This Report

Report ID 126540
Category Material & Chemical
Published Date Nov 2021
Updated Date
Contact Us